The neoantigen-targeted therapies industry is thawing and coming out of its biotech winter fuelled by Moderna’s recent news showing 49% decrease in disease progression after 5 years. This momentum has reignited confidence across pharma and biotech, accelerating a neoantigen programme and pushing more candidates into the clinic than ever before.

Time: 7:00 AM – 4:10 PM

Venue Details: Park Plaza Victoria Amsterdam, 1-5 Damrak, Amsterdam, Noord-Holland, 1012 TM, Netherlands

Category: Conferences

Prices: EUR 2499.00 – EUR 4797.00